UA121959C2 - Склад, який містить очищену рекомбінантну ідуронат-2-сульфатазу (i2s) - Google Patents

Склад, який містить очищену рекомбінантну ідуронат-2-сульфатазу (i2s) Download PDF

Info

Publication number
UA121959C2
UA121959C2 UAA201413826A UAA201413826A UA121959C2 UA 121959 C2 UA121959 C2 UA 121959C2 UA A201413826 A UAA201413826 A UA A201413826A UA A201413826 A UAA201413826 A UA A201413826A UA 121959 C2 UA121959 C2 UA 121959C2
Authority
UA
Ukraine
Prior art keywords
protein
recombinant
purified recombinant
column
approximately
Prior art date
Application number
UAA201413826A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дейв Ніколс
Дэйв Николс
Original Assignee
Шир Хьюман Дженетік Терапіс, Інк.
Шир Хьюман Дженетик Терапис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA121959(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Хьюман Дженетік Терапіс, Інк., Шир Хьюман Дженетик Терапис, Инк. filed Critical Шир Хьюман Дженетік Терапіс, Інк.
Publication of UA121959C2 publication Critical patent/UA121959C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
UAA201413826A 2012-06-29 2013-06-28 Склад, який містить очищену рекомбінантну ідуронат-2-сульфатазу (i2s) UA121959C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
UA121959C2 true UA121959C2 (uk) 2020-08-25

Family

ID=49778401

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201413826A UA121959C2 (uk) 2012-06-29 2013-06-28 Склад, який містить очищену рекомбінантну ідуронат-2-сульфатазу (i2s)
UAA201908350A UA129561C2 (uk) 2012-06-29 2013-06-28 Композиція для лікування синдрому хантера

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201908350A UA129561C2 (uk) 2012-06-29 2013-06-28 Композиція для лікування синдрому хантера

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP2867245B1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN107596357A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA3008945A1 (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA034549B1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL236315A (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX366906B (enExample)
MY (3) MY192068A (enExample)
NZ (3) NZ743910A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871A1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI587869B (enExample)
UA (2) UA121959C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
PL2485761T3 (pl) 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
WO2018038243A1 (ja) 2016-08-25 2018-03-01 Ｊｃｒファーマ株式会社 抗体融合蛋白質の製造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 酵素補充療法用酵素を含む融合タンパク質
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
EP3898689A1 (en) * 2018-12-20 2021-10-27 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
EP3917951A1 (en) * 2019-01-30 2021-12-08 Amgen, Inc Aflibercept attributes and methods of characterizing and modifying thereof
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
WO2022087229A1 (en) * 2020-10-23 2022-04-28 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
EP0750511B1 (en) 1994-03-16 2003-06-11 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
IL145893A0 (en) 1999-04-26 2002-07-25 Genentech Inc Cell culture process for glycoproteins
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
CA2383800A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
CA2400034A1 (en) 2000-02-17 2001-08-23 Incyte Genomics, Inc. Human kinases
JP2003527851A (ja) 2000-03-17 2003-09-24 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ７つのヒト卵巣および卵巣癌関連タンパク質
WO2001079444A2 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
KR100788093B1 (ko) 2002-04-26 2007-12-21 제넨테크, 인크. 단백질의 비친화성 정제
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
PL377731A1 (pl) * 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
SI3219795T1 (sl) * 2008-01-18 2024-10-30 Biomarin Pharmaceutical Inc. Izdelava akitvnih visoko fosforiliranih humanih encimov lizomske sulfataze in njihova uporaba
PL2485761T3 (pl) 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
JP6063380B2 (ja) * 2010-06-25 2017-01-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド サンフィリポ症候群ｂ型の処置
ES2754234T3 (es) 2010-06-25 2020-04-16 Shire Human Genetic Therapies Métodos y composiciones para la administración SNC de iduronato-2-sulfatasa
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012042857A1 (ja) 2010-09-28 2012-04-05 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) * 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
MY157087A (en) 2016-04-19
TWI553120B (zh) 2016-10-11
CL2014003567A1 (es) 2015-04-24
HK1209767A1 (en) 2016-04-08
MY192068A (en) 2022-07-25
PH12014502871B1 (en) 2015-02-23
DK2867245T3 (en) 2018-11-26
US12359178B2 (en) 2025-07-15
HUE040769T2 (hu) 2019-03-28
ZA201803289B (en) 2021-04-28
GT201400303A (es) 2017-08-31
ES2689468T3 (es) 2018-11-14
AU2016200469A1 (en) 2016-02-18
TW201410868A (zh) 2014-03-16
RS58005B1 (sr) 2019-02-28
JP2018121645A (ja) 2018-08-09
SG10201703489VA (en) 2017-05-30
US20240043817A1 (en) 2024-02-08
LT2867245T (lt) 2018-11-12
CA2877517C (en) 2018-07-31
CN104583225A (zh) 2015-04-29
WO2014005014A3 (en) 2014-02-27
US20240401010A1 (en) 2024-12-05
IL261264A (en) 2018-10-31
IL287057A (en) 2021-12-01
AU2013282395A1 (en) 2015-01-29
US20150313972A1 (en) 2015-11-05
US20210317426A1 (en) 2021-10-14
SG11201408761VA (en) 2015-01-29
MY180287A (en) 2020-11-27
AU2016200469B2 (en) 2017-10-12
PH12015502408B1 (en) 2020-02-14
UA129561C2 (uk) 2025-06-04
US11530393B2 (en) 2022-12-20
KR20200143339A (ko) 2020-12-23
PL2867245T3 (pl) 2019-02-28
US9492511B2 (en) 2016-11-15
US20190359958A1 (en) 2019-11-28
IL261264B (en) 2021-10-31
AU2018200230A1 (en) 2018-02-01
BR112014032567A2 (pt) 2017-08-01
CN107596358A (zh) 2018-01-19
HK1249027A1 (zh) 2018-10-26
EA034549B1 (ru) 2020-02-19
PH12014502871A1 (en) 2015-02-23
AR091647A1 (es) 2015-02-18
JP7594365B2 (ja) 2024-12-04
AU2013282395B2 (en) 2015-12-03
EA202090044A1 (ru) 2020-07-31
JP6505629B2 (ja) 2019-04-24
HK1209431A1 (en) 2016-04-01
DOP2014000294A (es) 2015-03-15
WO2014005014A2 (en) 2014-01-03
NZ743910A (en) 2019-12-20
CN107596357A (zh) 2018-01-19
KR20220002227A (ko) 2022-01-06
TR201815811T4 (tr) 2018-11-21
MX2015000190A (es) 2015-04-08
JP2020105209A (ja) 2020-07-09
US20140004096A1 (en) 2014-01-02
JP2015523072A (ja) 2015-08-13
IL236315A0 (en) 2015-02-26
ZA201409397B (en) 2019-10-30
KR20140002451A (ko) 2014-01-08
US10344270B2 (en) 2019-07-09
MX336715B (es) 2016-01-28
JP2016119911A (ja) 2016-07-07
EP2867245A4 (en) 2016-03-09
TWI587869B (zh) 2017-06-21
US20170073652A1 (en) 2017-03-16
CO7240396A2 (es) 2015-04-17
PT2867245T (pt) 2018-11-26
TW201703794A (zh) 2017-02-01
IL287057B1 (en) 2026-01-01
HRP20181897T1 (hr) 2019-01-11
KR20190064542A (ko) 2019-06-10
BR112014032567B1 (pt) 2022-09-13
PH12015502408A1 (en) 2018-03-26
JP6171007B2 (ja) 2017-07-26
CR20140588A (es) 2015-04-06
IL236315A (en) 2016-11-30
EA201492177A1 (ru) 2015-06-30
PE20150720A1 (es) 2015-05-16
CA2877517A1 (en) 2014-01-03
SI2867245T1 (sl) 2018-12-31
CA3008945A1 (en) 2014-01-03
AU2018200230B2 (en) 2020-01-02
HK1249026A1 (zh) 2018-10-26
AU2013282395C1 (en) 2016-03-24
EP2867245B1 (en) 2018-09-12
IL248727A0 (en) 2017-01-31
MX2019008914A (es) 2019-09-26
MX366906B (es) 2019-07-30
EP3441398A1 (en) 2019-02-13
US9051556B2 (en) 2015-06-09
KR20140004603A (ko) 2014-01-13
NZ733366A (en) 2019-12-20
EP2867245A2 (en) 2015-05-06
NZ703093A (en) 2017-08-25
SMT201800612T1 (it) 2019-01-11
MX393364B (es) 2025-03-19
KR101380740B1 (ko) 2014-04-11
PH12020500027A1 (en) 2021-03-15
CY1121519T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
UA121959C2 (uk) Склад, який містить очищену рекомбінантну ідуронат-2-сульфатазу (i2s)
HK1209767B (en) Purification of iduronate-2-sulfatase
EA049401B1 (ru) Очистка идуронат-2-сульфатазы